DDrare: Database of Drug Development for Rare Diseases

Searched query = "Pseudoxanthoma elasticum", "PXE"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.

Drug = Aflibercept; CAS No.: 7758-16-9; Disodium Pyrophosphate; Eylea; Intravitreal injection ranibizumab; LANSOPRAZOLE; Lansolprazole; Lansoprazole; Lansoprazole 30mg; Lucentis; Magnesium; Magnesium Oxide; Magnesium oxide; Pyrophosphate; RANIBIZUMAB; RFB002; RFB002, rhuFab V2; RFB002A; Ranibizumab; Ranibizumab injection (0.5 mg); RhuFab V2; SODIUM ACID PYROPHOSPHATE; SODIUM ACID PYROPHOSPHATE SAPP ROR 28 FOOD GRADE

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT01525875 (ClinicalTrials.gov)	August 2012	1/2/2012	Magnesium Supplements In The Treatment Of Pseudoxanthoma Elasticum (PXE)	Magnesium Supplements In The Treatment Of Pseudoxanthoma Elasticum (PXE)	Pseudoxanthoma Elasticum	Drug: Magnesium Oxide;Drug: Placebo	Mark Lebwohl	NULL	Completed	18 Years	N/A	All	44	Phase 2	United States

No.

TrialID

Date_
enrollment

Date_
registration

Public_title

Scientific_title

Condition

Intervention

Primary_
sponsor

Secondary_
sponsor

Recruitment_
Status

Inclusion_
agemin

Inclusion_
agemax

Inclusion_
gender

Target_
size

Phase

Countries

NCT01525875
(ClinicalTrials.gov)

August 2012

1/2/2012

Magnesium Supplements In The Treatment Of Pseudoxanthoma Elasticum (PXE)

Pseudoxanthoma Elasticum

Drug: Magnesium Oxide;Drug: Placebo

Mark Lebwohl

NULL

Completed

18 Years

N/A

All

Phase 2

United States